2023

ASSIGNMENT

TOPIC ANTI CANCER THERAPY

HCSUBJECT ADULT HEALT NURING
SUBMITTED TO MAM HUMAIRA
SUBMITTED BY ______________
SUBJECT ADULT HEALTH
NURSING
SUBMITTED DATE 15 /04/2023
 ANTICANCER DRUG THERAPY
ALKYLATING AGENT

PLATINIUM
COMPOUNDS

CYTOTOXIC ANTIMETABOLITIES

ANTICANCER
DRUG
DRUGS AFFECTING

ANTICANCER MITOTOC SPINDLE

DRUG
TOPOISOMERASE
INHIBITOR

MISCALLENOUS
DRUGS

TARGETED SMALL MOLECULES

ANTICANCER MONOCOLONAL
DRUG ANTIBODIES

ADVERSE EFFECT OF
EACH ANTI CANCER
DRUG.
 Bone marrow
supression
 Alopecia
1. ALKYLATING AGENT( NON SPECIFIC)  Diarrhea
 Hyperuricemia
IF Ifosfamide
BUS Busulfan
NOT Nitrosoureas
PRESENT Procarbazine
TAKE Temozolomide
MY Melphalan,mechlorethamine

CYCLE Cyclophosphamide

MOA

 Adding alkyl
group to n7
of

guanine(cancer cell)
 These whole class of drug cause two more specific side effect which
include
 Secondary leukemia
Sterility

1. IFOSFAMIDE AND CYCLOPHOSPHAMIDE CAUSE

HEMORRHAGIC CYCTITIS
2. BUSULFAN CAUSE PULMONARY FIBROSIS
3. NITROSOUREAS CAUSE DELAY BONE MARROW
SUPPRESSION AND NEUTROPENIA
4. PROCARBAZIBNE CAUSE DISULFIRAM LIKE REACTION.
2.PLATINIUM
COMPOUNDS (NON
SPECIFIC)
CIS PLATIN
CARBO PLATIN
OXALI PLATIN
MOA: SAME AS ALKYLATING
AGENT BUT INSTEAD OF ALKYL GROUP IT ADDS PLATINIUM IN
DNA OF NEOPLASTIC CELL
SIDE EFFECT :
SAME AS ALKYLATING SGENT
SOME MORE SIDE EFFECTS:
EMITOGENIC
NEPHROTOXIC
OTOTOXIC
3.ANTIMETABOLITIES (S PHASE)
1) DRUGS AFFECTING FOLIC ACID

2) DRUGS AFFECTING PURINE METABOLISM

3) DRUGS AFFECTING PYRAMIDINE METABOLISM

DRUGS AFFECTING FA METABOLISM

A)METHOTREXATE
COMMON SIDE EFFECT
 HEPATOTOXIC
 MEGALOBLASTIC ANEMIA
DRUGS AFFECTING PURINES
 6 MERCAPTOPURINES
 6 THIOGUANINE
 CLADRABINE
 FLUDRABINE
DRUGS AFFECTING
PYRAMIDINE
5 FLOROURACIL
CAPECETABINE
GEMCITABINE
CYTARABINE
4)DRUGS AFFECTING
ON MITOTIC
SPINDLE
VINCRESTINE
VINBLASTIN
PACLITAXEL
DOCETAXIL

IMPORTANT POINT
VINCRESTINE IS BONE MARROW SPARING DRUG ALONG WITH L –
ASPARGENASE AND BLEOMYCIN
5 ) TOPOISOMERASE INHIBITOR
IRINOTECAN(TOPOISOMERASE 1 INHIBITORS)
ETOPOSIDE( TOPOISOMERASE 2 INHIBITORS)
A. ANTHRACYCLINES( CARDIO TOXIC S/E)
 DOXORUBICIN
DONORUBICIN
6 ) MISC DRUGS
BLEOMYCIN
L ASPERGENASE
ARSENIC TRIOXIDE
THALIDOMIDE
2.TARGETED ANTICANCER DRUGS
A) SMALL MOLECULES
1) TYROSINE KINASE INHIBITORS
GENERAL PROPERTIES
ALL END WITH “NIB”
ORALLY EFFECTIVE
METABOLIZED BY MICROSOMAL ENZYMES
USES
1) CML 2) LUNG CARCINOMA
IMATINIB AFATINIB
NILOTINIB ERLOTINIB
DASATINIB CERITINIB
GEFITINIB
3) RENAL CELL CARCINOMA
PAZOTINIB
AXITINIB
SORAFENIB
SUNITINIB

4)HEPATOCELLULAR CARCINOMA SORAFENIB

5)GIST (GASTROINTESTINAL STROMAL TUMORS)
SUNITINIB
IMATINIB
REGORAFINIB
6) MALIGNANT MELANOMA
DABREFINIB
VEMURAFENIB
TRAMELTENIB
7) MEDULLARY CANCER OF THYROID
VANDETANIB
2)MONOCLONAL ANTIBODIES
Used for colorectal carcinoma CERUXIMAB
PANITUMUMAB
RITUXJMAB
TRASTUZUMAB
Used for NHL
USED FOR BREAST CANCER
USED FOR MULTIPLE MYELOMA
USED FOR SOFT TISSUE SARCOMA

END